Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL30901158 | 0.89 | PTGS2 (0.34) | SLC22A12GPR3PTGS2 | |
| Trifluoromethanesulfonic Acid SCHEMBL29839677 | 0.85 | GPR3 (0.36) | GPR3PTGS2EPAS1 | |
| Trifluoromethanesulfonic Acid SCHEMBL31576440 | 0.83 | ALDH1A1 (0.41) | GPR3PTGS2 | |
| Trifluoromethanesulfonic Acid SCHEMBL29443425 | 0.82 | GPR3 (0.40) | GPR3PTGS2EPAS1 | |
| Trifluoromethanesulfonic Acid SCHEMBL31576455 | 0.82 | KMT2A (0.37) | GPR3PTGS2 | |
| Trifluoromethanesulfonic Acid SCHEMBL31322589 | 0.80 | FFAR4 (0.35) | GPR3PTGS2 | |
| Trifluoromethanesulfonic Acid SCHEMBL29462458 | 0.80 | RAPGEF4 (0.41) | GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL29462456 | 0.79 | GPR3 (0.41) | GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL31135514 | 0.78 | GPR3 (0.43) | GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL5707355 | 0.77 | GPR3 (0.41) | GPR3PTGS2EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2025-12-25 | — | — | US | disclosed |
| EP-4556476-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | Ildong Pharmaceutical Co., Ltd. (KR) | 2025-05-21 | — | — | EP | disclosed |
| WO-2024014885-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | 일동제약(주) | 2024-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | GBA1, PIKFYVE, MAN2B1 | SLC22A12 1657/4885GPR3 2521/4885PTGS2 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.